XML 63 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
BUSINESS SEGMENT INFORMATION
 12 Months Ended
Dec. 31, 2014
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]
BUSINESS SEGMENT INFORMATION
BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the development and delivery of products to the market. Regional commercial organizations are used to distribute and sell the product. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.
Products are sold principally to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. Gross revenues to the three largest pharmaceutical wholesalers in the U.S. as a percentage of global gross revenues were as follows:
 
 
2014
 
2013
 
2012
McKesson Corporation
 
20
%
 
19
%
 
23
%
Cardinal Health, Inc.
 
12
%
 
14
%
 
19
%
AmerisourceBergen Corporation
 
17
%
 
15
%
 
14
%

Selected geographic area information was as follows:
 
 
Total Revenues
 
Property, Plant and Equipment
Dollars in Millions
 
2014
 
2013
 
2012
 
2014
 
2013
United States
 
$
7,716

 
$
8,318

 
$
10,384

 
$
3,686

 
$
3,708

Europe
 
3,592

 
3,930

 
3,706

 
597

 
729

Rest of the World
 
3,459

 
3,295

 
3,204

 
134

 
142

Other(a) 
 
1,112

 
842

 
327

 
—

 
—

Total
 
$
15,879

 
$
16,385

 
$
17,621

 
$
4,417

 
$
4,579


(a)
Other total revenues include royalties and other alliance-related revenues for products not sold by our regional commercial organizations.
Total revenues of key products were as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2014
 
2013
 
2012
Virology
 
 
 
 
 
 
Baraclude (entecavir)
 
$
1,441

 
$
1,527

 
$
1,388

Hepatitis C Franchise(a)
 
256

 
—

 
—

Reyataz (atazanavir sulfate)
 
1,362

 
1,551

 
1,521

Sustiva (efavirenz) Franchise(b)
 
1,444

 
1,614

 
1,527

Oncology
 
 
 
 
 
 
Erbitux* (cetuximab)
 
723

 
696

 
702

Opdivo (nivolumab)
 
6

 
—

 
—

Sprycel (dasatinib)
 
1,493

 
1,280

 
1,019

Yervoy (ipilimumab)
 
1,308

 
960

 
706

Neuroscience
 
 
 
 
 
 
Abilify* (aripiprazole)(c)
 
2,020

 
2,289

 
2,827

Immunoscience
 
 
 
 
 
 
Orencia (abatacept)
 
1,652

 
1,444

 
1,176

Cardiovascular
 
 
 
 
 
 
Eliquis (apixaban)
 
774

 
146

 
2

Diabetes Alliance(d)
 
295

 
1,683

 
972

Mature Products and All Other(e)
 
3,105

 
3,195

 
5,781

Total Revenues
 
$
15,879

 
$
16,385

 
$
17,621


(a)
Includes Daklinza (daclatasvir) revenues of $201 million and Sunvepra (asunaprevir) revenues of $55 million in 2014.
(b)
Includes alliance and other revenues of $1,255 million in 2014, $1,366 million in 2013 and $1,267 million in 2012.
(c)
Includes alliance and other revenues of $1,778 million in 2014, $1,840 million in 2013 and $2,340 million in 2012.
(d)
Includes Bydureon* (exenatide extended-release for injectable suspension), Byetta* (exenatide), Farxiga*/Xigduo* (dapagliflozin/dapagliflozin and metformin hydrochloride), Onglyza*/Kombiglyze* (saxagliptin/saxagliptin and metformin), Myalept* (metreleptin) and Symlin* (pramlintide acetate). BMS sold its diabetes business to AstraZeneca on February 1, 2014.
(e)
Includes Plavix* (clopidogrel bisulfate) revenues of $208 million in 2014, $258 million in 2013 and $2,547 million in 2012. Additionally, includes Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide) revenues of $211 million in 2014, $231 million in 2013 and $503 million in 2012.